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Diﬀuse large B-cell lymphomas have been little studied in black Africans. The purpose of our study was to determine the
characteristicsandresultsofthemanagementoftheselymphomas.PatientsandMethods.Inadescriptiveandanalyticretrospective
study we studied the medical records of 63 patients with diﬀuse large B-cell lymphoma hospitalized during the period from 1991
to2007.Thediagnosiswasmadeafterlymphnodeororganbiopsy.Responsetotreatment,OS,PFS,andtoxicitywerestudied.The
complete response has been analyzed univariate and multivariate analysis. Results. The median age was 42 years. The sex ratio was
2. The HIV serology was positive in 11 cases, and 8 patients had antiretroviral therapy. In 71% the lymphoma was at stages III and
IV of Ann Arbor. IPI was ≥3 in 65%. Complete remission was achieved in 43%. Only 43% of patients had had a good compliance.
Progression-free survival at 3 years was 32%, and overall survival at 3 years was 50%. 13% of patients were lost to follow up,
and 51% of them died. In terms of analysis the complete remission rate was inﬂuenced by the stage of Ann Arbor (P<0.0001),
biological b symptoms (P<0.01), the IPI (P<0.0001), and the socioeconomic standing (P = 0.001). In multivariate analysis,
only IPI and stage of Ann Arbor inﬂuence the complete remission.
1.Introduction
DiﬀuselargeB-celllymphomasareclonalproliferationsofB-
lymphocytes. It is the most common form of non-Hodgkin’s
lymphomas accounting for 30 to 40% of lymphomas in
adults [1, 2]. They are aggressive because the cells are young
and express the proliferation marker Ki 67+. Thus, the
doubling of the tumor mass is rapid, in the order of 15 days
to one month. Diﬀu s el a r g eB - c e l ll y m p h o m a sc o n s t i t u t ea
heterogenous group with at least 15 entities according to the
2008 World Health Organization (WHO) classiﬁcation and
two molecular subtypes: those of germinal center type and
those of activated B-cells type [3, 4]. These lymphomas may
originate in the lymph nodes or in extranodal sites; they can
be localized or disseminated.
In terms of therapy, these lymphomas are usually sensi-
tive to chemotherapy including CHOP protocol (Cyclophos-
phamide, Doxorubicin, Vincristine, and Prednisone), which
has been used since 1973 [5]. Then appeared the 3rd and
2nd generation protocols, which improved the complete
remission rate. At the moment, Rituximab combined with
CHOP, used in the ﬁrst line, has further improved complete
remission rate and survival. This treatment is adapted to the
Internal Prognostic Index (IPI), which consists of 5 factors:
age, performance score, stage of Ann Arbor, LDH rate, and
extra-nodal aﬀection. These diﬀuse large B-cell lymphomas
have been little studied in black Africans. The purpose of
our study was to determine the results of the management
of these lymphomas.
2. Patients andMethods
Our study was carried out in the Department of Clinical
Hematology of Yopougon Teaching Hospital of Abidjan,
Cˆ ote d’Ivoire from July 1991 to September 2007. Patients2 Advances in Hematology
hospitalized with diﬀuse large B-cell lymphoma of histolog-
ical and immunohistochemical diagnosis (CD 19, CD 20,
CD 22, and CD 79a) after lymph node or organ biopsy,
with a complete medical record and who received CHOP
protocol for treatment. Diﬀuse large B-cell lymphomas
after transformation of a follicular lymphoma and primitive
diﬀuse large B-cell lymphomas of the central nervous system
were excluded. Sixty-three records were selected. The study
was retrospective, descriptive, and analytic. Each medical
record was operated using a survey form. The collection of
data in the record looked for epidemiological parameters:
age, sex, socioeconomic standing, and history of exposure
to known etiologic factors. The clinical status took into
account the general condition (weight loss, profuse night
sudation, fever, and index of the activity of the WHO) as
well as the various devices in the search for tumor lesion
or other. Para-clinically, a lymph node or organ biopsy with
pathological examination was performed. In each patient a
cervicothoracic and abdominopelvic computed tomography
(CT scan), a bone marrow biopsy, a lumbar puncture
with cytological study of the cerebrospinal ﬂuid, a check-
up of biological course (blood count, ﬁbrinemia, LDH, β2
microglobulin, protein electrophoresis, serum electrolytes,
uric acid) and a pretherapeutic check-up (liver and kidney
check-up, echocardiography, HIV status, and B and C viral
serology) were performed. In terms of therapy, chemother-
apy with CHOP protocol was assessed (6 to 9 cycles were
planned)andprognosticfactorswereidentiﬁedbyunivariate
and multivariate analysis of the therapeutic response.
The results of midterm assessment of chemotherapy and
postchemotherapy were clinical, biological, and radiological
(CT scan).
Complete remission was characterized by the disappear-
anceofalltumorsitesconﬁrmedbytheresultsofassessment.
Partial remission corresponded to a partial regression of the
tumor and failure to an absence of remission.
Therapeutic compliance is deﬁned by the regularity of
chemotherapy administration. Patients who received treat-
ment every 21 days had a good compliance; on the other
hand, those who had the treatments with intervals superior
than 21 days had a poor compliance.
The assessment of the socioeconomic level was done
according to indirect criteria, which were occupation, num-
ber of children, and type of housing.
Overall survival (OS) was calculated from the date of
biopsy to the time of death or to the time of the last follow-
up. Progression-free survival (PFS) was calculated from the
date of biopsy to the time of relapse, progression, death, or
the last follow-up.
Our study has been approved by an Ethics Committee,
and has been conducted in accordance with the Declaration
of Helsinki. Appropriate written consent for the CHOP
treatement was obtained.
The collected data were analyzed with the software
program Epi-Info 6.04b and Stat view 5.0. The statistic
analysis used the calculation of averages and the Khi2 test.
The level of signiﬁcance was set at 5% for the value of P.T h e
calculation of survival was done according to Kaplan-Meir’s
method thanks to the existence in the record of a date of
Table 1: CHOP protocol.
CHOP Every day Day
Drugs Dose and
administration route
Cyclophosphamide 750mg/m2 IV Day 1
Adriamycin 50mg/m2 IV Day 1
Vincristine 1.4mg/m2 IV Day 1
Prednisone 100mg/m2 per oral
route Days 1 to 5
inclusion (date of admission) and a date of assessment (date
of death or late news) mentioned by day, month, and year.
CHOP protocol is shown in Table 1.
3. Results
3.1. Descriptive Results. General characteristics (epidemio-
logical, and clinical) are presented in Table 2, and biological
characteristics of patients in Table 3.
Out of a total of 63 patients, the median age was 42 years
with extremes of 12 and 75 years. The sex ratio was 2.
In 68% patients were referred to the Department of
Clinical Hematology with their diagnosis of lymphoma.
In 32% it was for polyadenopathy, or splenomegaly or
hepatomegaly. The delay of consultation was less than 3
months in 24%, 3 to 6 months in 41%, and more than 6
months in 35%.
Concerning HIV infection, 11 patients (17%) were
positive; 8 patients (13%) were on antiretroviral treatment
w i t har a t eo fC D 4> 200/mm3. In 3 patients (6%) the rate of
CD4 was <50/mm3.
As for the treatment (Table 4) the remission rate was
83%, with 43% of complete remission and 40% of partial
remission. The rate of failure was 17%.
Toxicity related to the treatment was hematological (23
cases, i.e. 37%) and required hematological resuscitation
and the administration of growth factor (G-CSF). Metabolic
toxicity came into the second position with 20 cases, that is,
32%, with hyperkalemia and/or hyperphosphatemia and/or
hypocalcemiaand/orincreasedlevelofLDH.Othertoxicities
were brought out: digestive toxicity (7 cases i.e., 11%),
cardiac toxicity (3 cases, i.e., 5%), neuropathies (3 cases, i.e.,
5%), alopecia (2 cases, i.e., 3%).
The median follow-up duration was 3 years. Median OS
was 49% and median PFS was 32%. They were, respectively,
(OS and PFS) 78% and 74% at 3 years for patients with IPI
at 0 and 1 and 29% and 26% for those with IPI ≥ 3.
Evolution to death was observed in 32 cases, that is, 51%.
It was a progression of the disease in 17 cases (27%), and
of hematological toxicity in 7 cases (11%), of infections in
4 cases (6%), of metabolic toxicity in 2 cases (3%), and in
2 cases (3%) the cause of death was undetermined. Seven
patients out of 11 with HIV died.
The overall survival study is represented in Figure 1,wi t h
the months on axis.Advances in Hematology 3
Table 2: General characteristics of patients.
Parameters Number (%)
n = 63
Age (years), median age: 42 years
<60 52 (83)
≥60 11 (17)
Sex
Male 42 (67)
Female 21 (33)
Socioeconomic class
Low 32 (51)
Medium 22 (35)
High 9 (14)
Site of lymphoma
Nodal 37 (59)
Extra-nodal 6 (9)
Mixed 20 (32)
Extranodal sites
Gastrointestinal 7 (11)
Hepatic 6 (10)
Otorhinolaryngology 4 (6)
Pleuropulmonary 4 (6)
Genital 2 (3)
Bone 1 (2)
Stage of Ann Arbor
I, II 18 (29)
III, IV 45 (71)
IPI
Low risk (0, 1) 13 (21)
Intermediate low risk (2) 9 (14)
Intermediate high risk (3) 24 (38)
High risk (4, 5) 17 (27)
Clinical B symptoms
No 16 (25)
Yes 47 (75)
Biological b symptoms
No 26 (41)
Yes 37 (59)
3.2. Analytic Results. The relationship between the thera-
peutic response and the general characteristics of patients is
given in Table 5, with univariate analysis.
In multivariate analysis, only IPI (P = 0.001) and stage
of Ann Arbor (P = 0.01) are signiﬁcantly related to complete
remission.
4. Discussion
Inourstudy,patient’smedianagewas42yearswithextremes
of 12 and 75 years. Diﬀuse large B-cell lymphoma can occur
at any age but most patients were less than 60 years. The
median age of discovery is, however, variable depending on
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Figure 1: Overall survival curve of the patients with DLBCL.
Kaplan-Meier Graphe de Survie Cum. Pour Colonne 1 Variable
censure: <Sans>.
Table 3: Biological characteristics of patients.
Parameters Number (%) n = 63
Hepatic serology
B positive 3 (5)
C positive 2 (3)
Negative 5 (8)
Not speciﬁed 53 (84)
HIV serology
Positive 11 (17)
Negative 12 (19)
Not speciﬁed 40 (64)
LDH rate
Normal 7 (11)
High 56 (89)
β2 microglobulin rate
Normal 6 (10)
High 57 (90)
subtypes, on an average of 58 years for the forms of the
germinalcenter,66yearsfortheactivatedforms,and35years
for mediastinal forms [4].
The low median age of our study could be an epi-
demiological factor particularity of diﬀuse large B-cell
lymphoma in black Africans. Indeed, recent data in the
United States suggest that the age of onset of diﬀuse
large B-cell lymphomas was lower in black Americans [4]
compared to Caucasians. The sex ratio was 2. This male
predominanceisconﬁrmedbyseveralauthorsinthewest[6–
8]. In 68% of cases patients were referred to the Department
of Clinical Hematology with their diagnosis of lymphoma.
This demonstrates the readiness of general practitioners to
perform lymph node or organ biopsies when faced with
any lymphadenopathy or suspicious lesion, but consultation
period was most often long, between 3 and 6 months in
41% and more than 6 months in 35%. Long consultation
periods are partly due to ignorance of patients who consult4 Advances in Hematology
Table 4: Therapeutic and evolutional characteristics of patients.
Parameters Number (%) n = 63
Type of therapy
CHOP 63 (100)
RCHOP 0 (0)
Therapeutic response
Complete remission 27 (43)
Partial remission 25 (40)
Failure 11 (17)
Dose adherence
Normal 61 (97)
Reduction 2 (3)
Delay of chemotherapy (days)
<15 44 (70)
15–30 14 (22)
>30 5 (8)
Treatment compliance
Good 27 (43)
Poor 36 (57)
Toxicity
Hematological 23 (37)
Metabolic 20 (32)
Digestive 7 (11)
Cardiac 3 (5)
Neuropathies 3 (5)
Alopecia 2 (3)
Number of cycles
4–7 46 (73)
>7 17 (27)
Outcome at median follow-up
Progression-free survival 20 (32)
Overall survival 31 (49)
Lost to follow-up 8 (13)
Dead 32 (51)
Causes of death
Progression 17 (27)
Hematological toxicity 7 (11)
Infection 4 (6)
Metabolic toxicity 2 (3)
Undetermined 2 (3)
traditional doctors ﬁrst before going to hospital. This delay
in diagnosis is one of the arguments in favor of the spread
of the disease. This is the reason why 71% of patients were
at stages III and IV of Ann Arbor. But this rapid spread of
the disease may be a clinical particularity of diﬀuse large B-
cell lymphomas in the black Africans. Actually according to
Flowers [4], black Americans present a more advanced stage
of the disease (III and IV). This has been demonstrated in
retrospective cohort studies [9, 10]. This particular clinical
presentation is not related to HIV infection according to
these authors.
In our study we could not draw any conclusion regarding
HIV infection because serology was not performed in 64%
of our patients. Nevertheless, it was positive in 11 patients
out of 23, that is, 48%. There is ample evidence that HIV
infectionandimmunosuppressionresultingfromitincreases
the risk of developing cancer in general and in particular
lymphomas [11–13]. According to some authors [14, 15]
lymphomas occurring during HIV infection are usually B-
cell lymphomas that are particularly centroblastic, diﬀuse,
histiocytic, or immunoblastic. Future studies will determine
the impact of racial, geographical, and environmental factors
on the clinical presentation of these diﬀuse large B-cell
lymphomas. 75% of patients presented at least a sign of
clinical B symptoms in our series whereas in western series,
1/3 of patients presented B symptoms. This is probably due
to the delay in consultation and also to the disseminated
character of the disease [4, 16–18].
In terms of therapy, diﬀuse large B-cell lymphomas are
very chemosensitive and curative even in the disseminated
forms [5]. Our patients had had CHOP 21 protocol, which
has for a long time been the standard treatment of diﬀuse
large B-cell lymphomas [4]. With this protocol, the global
response was 83%. We obtained 27 cases of complete
remission, that is, 43%, 25 cases of partial remission, that
is, 40% and 11 cases of failure, that is, 17%. Our complete
remission rate is below that of western, American, and
Asian authors who have complete remission rates ranging
from 60 to 80% on CHOP [2, 4, 5, 19]. This low rate of
complete remission could be explained by the number of
cycles received by patients on the one hand and on the
other hand by the therapeutic compliance and the delay of
chemotherapy. Indeed, out of 6 to 9 cycles of chemotherapy
planned 23% of patients received less than 6 cycles. This
is due to the very poor socioeconomic standing of most
of our patients. 51% of our patients were from a lower
socioeconomic class, whereas the treatment is relatively
expensive. Another argument that helped explain this low
rate of complete remission was the poor compliance related
to treatment (57%). In 43% of cases patients respected
the interval between two treatments, which was 21 days.
This interval was long in the 57%. Besides, 41% of our
patients had an IPI ≥ 3 and therefore several factors of
poor prognosis. To improve our rate of complete remission,
the institution of immunotherapy with Rituximab combined
with CHOP (R-CHOP), which gives complete remission
in the range of 80% would be an interesting alternative
[4, 19, 20]. But the high cost of this drug makes it out of
reach for the majority of our patients. 2nd-generation pro-
tocols such as mBACOD (Methotrexate, Bleomycin, Adri-
amycine, Cyclophosphamide, Vincristine, Dexamethasone)
or 3rd-generation protocols such as ACVBP (Adriamycine,
Cyclophosphamide, Vincristine, Bleomycine, Prednisone),
which provide complete remission rates in the range of 70 to
80%, arediﬃculttohandleinourcontextofexercisebecause
of the chemo-induced aplasia they cause besides being
expensive. CHOP 14 which consists in the administration of
CHOP every 14 days is diﬃcult to institute in our practiceAdvances in Hematology 5
Table 5: Relationship between the therapeutic response and the
general characteristics of patients.
Parameters Univariate analysis
Complete response P
Age (years)
<60 22/52 (42) 0.552
≥60 5/11 (45)
Sex
Male 18/42 (43) 0.787
Female 9/21 (43)
Socioeconomic standing
Low 7/32 (22)
0.001 Medium 13/22 (59)
High 7/9 (77)
IPI
Low risk (0, 1) 5/6 (83)
<0.0001 Intermediate risk (2) 13/16 (81)
High risk (≥3) 9/41 (22)
Site
Nodal 18/37 (49) 0.395
Extranodal 9/26 (35)
Consultation period
(month)
<3 10/15 (67)
0.06 3–6 10/26 (38)
>6 7/22 (32)
Stage of Ann Arbor
I, II 16/18 (89) <0.0001
III, IV 11/45 (24)
Clinical B symptoms
No 8/16 (50) 0.706
Yes 19/47 (40)
Biological b symptoms
No 17/26 (65) 0.01
Yes 5/37 (13)
sinceitrequiresgrowthfactors(G-CSF)thatincreasethecost
of treatment [5].
In terms of outcome, we obtained 20 cases of progression
free survival, that is 32%, 8 patients were lost to follow up,
that is, 13%, and 32 patients died, that is, 51% after 3 years
of median follow-up. Our rate of progression-free survival
at 3 years, which was 32%, is below the rate in the west, on
CHOP. According to the Groupe d’Etudes des Lymphomes
de l’Adulte, progression-free survival at 10 years and the
global survival at 10 years were, respectively, 20% and 27.6%
on CHOP [21]. Our low rate, of progression-free survival at
3yearsisrelatedtoourcompleteremissionratewhichisonly
27%. 13% of patients were lost to follow up. These patients,
most of the time, ﬁnancially exhausted deliberately stopped
their follow-up.
In terms of analysis, parameters that could inﬂuence
the complete remission rate were studied. The stage of Ann
Arbor, biological b symptoms, the International Prognosis
Index (IPI), and the socioeconomic standing are the four
parameters that inﬂuence the complete remission rate in
univariate analysis. In localized stages I and II of Ann
Arbor the complete remission rate was 89% whereas this
rate dropped to 24% in advanced stages III and IV (P<
0.0001). In the group with no of biological b symptoms,
the complete remission rate was 65% and 27% in group
with yes (P<0.01). The complete remission rate was 83%
in the low-risk group versus 22% in the high-risk group
(P<0.001). The socioeconomic standing also inﬂuences
the complete remission rate. This rate was 22% in the low
socioeconomic class, 81% in the medium socioeconomic
class, and 78% in the high socioeconomic class (P =
0.001). The socioeconomic standing, which then constitutes
a prognostic factor, is generally one of the particularities
of the management of hematologic malignancies in our
country. In multivariate analysis, only the IPI (P = 0.001)
andthestageofAnnArbor(P = 0.01)inﬂuencethecomplete
remission rate.
5. Conclusion
Diﬀuse large B-cell lymphoma in black Africans presents
some epidemiological, clinical, therapeutic, and prognostic
particularities: the age of onset is lower, the disease is more
disseminated (stages III and IV of Ann arbor), the complete
remission rate is low, the socioeconomic standing constitutes
a signiﬁcant prognostic factor, and some patients are lost to
follow up.
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